He had stopped driving two years prior because he could no longer "see movement while driving". His wife noted that he could not judge the speed of another car or how far away it was. He had difficulty watching television with significant action or movement, such as sporting events or action-filled TV shows. He frequently commented to his wife that he could not "see anything going on". When objects began to move they would disappear. He could, however, watch the news, because no significant action occurred. In addition he had signs of Balints syndrome (mild simultanagnosia, optic ataxia, and optic apraxia). Pelak and Hoyts TBI patient
In 2003, a 60-year-old man complained of the inability to perceive visual motion following a traumatic brain injury, two years prior, in which a large cedar light pole fell and struck his head. He gave examples of his difficulty as a hunter. He was unable to notice game, to track other hunters, or to see his dog coming towards him. Instead, these objects would appear in one location and then another, without any movement being seen between the two locations. He had difficulties driving and following a group conversation. He lost his place when vertically or horizontally scanning a written document and was unable to visualize three-dimensional images from two-dimensional blueprints. == References ==
Caused by glycoprotein abnormalities: Bernard–Soulier syndrome, velocardiofacial syndrome
Caused by calpain defect: Montreal platelet syndrome
Caused by alpha granules defect: gray platelet syndrome
Characterized by  abnormal neutrophil inclusions: May–Hegglin anomaly, Sebastian syndrome
With systemic manifestations: Hereditary macrothrombocytopenia with hearing loss, Epstein syndrome, Fechtner syndrome
With no specific abnormalities: Mediterranean macrothrombocytopenia
Harris platelet syndrome

Treatment
There has been no general recommendation for treatment of patients with giant platelet disorders, as there are many different specific classifications to further categorize this disorder which each need differing treatments. Platelet transfusion is the main treatment for people presenting with bleeding symptoms. There have been experiments with DDAVP (1-deamino-8-arginine vasopressin) and splenectomy on people with giant platelet disorders with mixed results, making this type of treatment contentious. References


== External links ==